HLA-A11 restricted and carcino-embryonic antigen originated epitope peptide and application thereof

A HLA-A11, restricted technology, applied in the field of biomedicine

Active Publication Date: 2016-07-13
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for safe and effective induction of specific antibodies by modifying certain parts or substances found on cells called histones that make up DNA (the genetic material used to store life). These modifications help protect it from being copied into other organisms without harming them permanently.

Problems solved by technology

Technological Problem addressed in this patents relates to finding new targets associated with carboxypeptidase-4/7 (CAMPE), specifically CEL protein involved in autoimmune responses against various diseases like lung cancer. Current methods involve studying individual markers' ability to react strongly with these proteins but their role may vary depending upon patient characteristics. Additionally, current methodologies require large amounts of DNA material to identify relevant ones.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HLA-A11 restricted and carcino-embryonic antigen originated epitope peptide and application thereof
  • HLA-A11 restricted and carcino-embryonic antigen originated epitope peptide and application thereof
  • HLA-A11 restricted and carcino-embryonic antigen originated epitope peptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Screening of HLA-A11 High Affinity Polypeptides

[0037] First, the primary sequence of the CEA antigen was analyzed by online biological software (SYFPEITHI, BIMAS and NetMHC) using HLA-A*1101, and 5 antigens that were likely to bind to HLA-A11 and induce the body to produce CTL were selectively synthesized peptide. See Table 1 for the sequence. We screened these peptides using LoVo cells because:

[0038] LoVo cells are colon tumor cells derived from HLA-A11 and highly expressing CEA. However, as detected by flow cytometry, LoVo expressed very low levels of MHC-I and HLA-A11. It is well known in the field of immunology that all nucleated cells in the body express MHC-I molecules, which can be regarded as antigen-presenting cells in a broad sense. The low expression of MHC-I in tumor cells, on the one hand, cannot effectively induce the body to produce CTL, on the other hand, it escapes being recognized by CTL and is cleared. One mechanism for the low ex...

Embodiment 2-4

[0043] Example 2-4 Induction of HLA-A11-restricted CEA 636-644 Generation of specific CTL

[0044] 1. Preparation of human monocyte-derived dendritic cells (MoDC)

[0045] Separation of CD14 from peripheral blood of HLA-A11 positive healthy people by immunomagnetic bead method + Monocytes were immature MoDC after being induced by human recombinant GM-CSF (50ng / ml) and IL-4 (10ng / ml) for 5 days.

[0046] 2. Sensitization of DC

[0047] There are two methods:

[0048] 2.1 will carry CEA containing 636-644 Peptide CEA 576-669 The recombinant adenovirus (AdCEA 576-669 HSP70L1 (AdCH for short) vector was used to infect human immature MoDC, and after 48 hours, the AdCH-infected human immature MoDC (AdCH-DC) was collected, which was intracellular sensitized DC. As a control, MoDC (AdLacZ-DC) infected with a recombinant adenovirus carrying the LacZ gene was used.

[0049] 2.2 Use CEA directly 636-644 The peptide (50μg / ml) was cultured with human immature MoDC overnight, which...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of biomedicine, in particular to a CEA (carcino-embryonic antigen) originated and HLA-A11 restricted CTL (cytotoxic T lymphocyte) epitope peptide and application of an epitope peptide coding gene, a recombinant protein or compound containing the epitope peptide, a sensitizing antigen presenting cell and a specific immunity effector cell aiming at the epitope peptide to preparation of medicines for treating CEA positive tumors.The CEA originated and HLA-A11 restricted CTL epitope peptide is capable of safely and effectively inducing immune response aiming at CEA and significant to researches on CEA positive tumor pathogenesis and development of known efficacies of vaccines for the CEA positive tumors.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap